No, you do not need pre-market FDA approval to sell a private label peptide under eye serum in the United States, provided your product is marketed as a cosmetic and not as a drug.
Under US law, a product is a cosmetic if it is intended to affect appearance — to make skin look smoother, to reduce the visible appearance of puffiness, to brighten the look of the under-eye area. A product becomes a drug if it is intended to affect the structure or function of the body. Marketing language like 'clinically treats dark circles' or 'reverses collagen loss' crosses into drug territory and triggers FDA drug regulations, which require premarket approval and are functionally impossible to comply with for a small brand.
The practical guidance: use appearance-based claims. 'Visibly reduces the appearance of fine lines' is cosmetic language. 'Reduces wrinkles' without the qualifier 'appearance of' is borderline. 'Stimulates collagen production' is a drug claim and must be avoided on labels and in advertising.
The Modernization of Cosmetics Regulation Act (MoCRA), signed in December 2022, introduced new requirements that do apply to your brand. If you are a small business (under $1 million in gross sales averaging over three years), some requirements are phased or waived, but you should verify your status. For brands above the threshold, facility registration and product listing with the FDA are now required. Good Manufacturing Practice (GMP) requirements under MoCRA are being phased in, with final rules expected to be enforceable by 2025 and 2026.
Serious adverse event reporting is also now required under MoCRA regardless of company size. If a consumer reports a serious adverse event linked to your eye serum, you must submit a report to the FDA within 15 business days.
Labeling requirements that absolutely apply: ingredient declaration in INCI format in descending order of concentration, net weight or volume, distributor name and address, and any required warnings. Eye-area products must not include ingredients that are prohibited or restricted for use near the eyes under 21 CFR.
For California specifically, Prop 65 compliance is a separate obligation. If any ingredient in your formula appears on the Prop 65 list above its safe harbor level, a warning must appear on the label for California consumers.
Manufacturers you connect with through AJ Cosmo Labs are expected to hold GMP certification and be familiar with MoCRA requirements — you should still verify this directly during onboarding.
Read the full guide on Private Label Peptide Under Eye Serum Manufacturer →